EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY 4.0

Characterization and comparison of immunity against MPXV for individuals infected with MPXV or vaccinated with modified vaccinia Ankara vaccines

Aurélie Wiedemann iD, Mathieu Surénaud, Mathieu Hubert, José-Luis Lopez Zaragoza, Alexandre Ribeiro, Cécile Rodrigues, Emile Foucat, Harouna Diombera, Corinne Krief, Olivier Schwartz, Jean-Daniel Lelièvre, Yves Lévy iD

The Journal of Immunology · 2025

DOI: 10.1093/jimmun/vkae031 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift The Journal of Immunology, 2025. Verfasst von Aurélie Wiedemann und 11 weiteren Autor:innen. Beteiligte Einrichtung: Vaccine Research Institute, Université Paris-Est Créteil, Créteil, France. Hauptthemen laut MEDLINE: CD8-Positive T-Lymphocytes, Smallpox Vaccine, Viral Vaccines, Mpox, Monkeypox. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Institut National de la Santé et de la Recherche Médicale, Vaccine Research Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The 2022 Mpox virus (MPXV) outbreak revitalized questions about immunity against MPXV and vaccinia-based vaccines (VAC-V), but studies are limited. We analyzed immunity against MPXV in individuals infected with MPXV or vaccinated with the licensed modified vaccinia Ankara (MVA) Bavarian Nordic or an experimental MVA-HIVB vaccine. The frequency of neutralizing antibody responders was higher among MPXV-infected individuals than MVA vaccinees. Both MVA vaccines induced similar and strong humoral responses. Similarly, we show a higher frequency and magnitude (5-fold) of T cell responses, mainly mediated by CD8+ T cells, against a peptide pool containing selected sequences from MPXV, variola, and VAC-V in MPXV-infected individuals than MVA vaccinees. We describe a hierarchy of cross-reactive T cell responses against 5 peptide pools that are highly homologous between VAC-V and MPXV 2022, with the highest frequency of responders against MVA-121L and MVA-018L proteins. Both vaccines stimulated a notable frequency of polyfunctional CD4+ and CD8+ T cell responses, with a subset of CD4+ T cells showing a mixed cytokine profile. Finally, we found that smallpox vaccination in childhood positively affected humoral but not T cell vaccine responses, whereas these responses were not affected in people living with HIV. These findings contribute to deciphering and monitoring the profile of immunity to MPXV and MVA. In the context of a potential threat of the reemergence of smallpox following bioterrorism, the diversification and availability of potent vaccines is crucial. The comparable immunogenicity of both MVA vaccines emphasizes the potential utility of MVA-HIVB as a valuable new tool for controlling MPXV outbreaks.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CD8-Positive T-LymphocytesSmallpox VaccineViral VaccinesMpox, MonkeypoxAdolescentAdultFemaleHumansMaleMiddle AgedYoung AdultAIDS VaccinesAntibodies, NeutralizingAntibodies, ViralCD4-Positive T-LymphocytesCross ReactionsVaccinationVacciniaVaccinia virusVaccines, DNA

Stichwörter der Autor:innen

MpoxT cellshumanvaccinationviral

Substanzen

AIDS VaccinesAntibodies, NeutralizingAntibodies, ViralMVA vaccineSmallpox VaccineViral VaccinesVaccines, DNA

Autor:innen und Institutionen

  • Vaccine Research Institute, Université Paris-Est Créteil, Créteil, France.
  • INSERM U955, Institut Mondor de Recherche Biomedicale, Team Lévy, Créteil, France.
  • Virus and Immunity Unit, CNRS UMR3569, Institut Pasteur, Université Paris Cité, Paris, France.
  • Groupe Henri-Mondor Albert-Chenevier, Service Immunologie Clinique, Assistance Publique-Hôpitaux de Paris, Créteil, France.

ORCID-Profile: Aurélie Wiedemann, Yves Lévy

Förderung

  • Institut National de la Santé et de la Recherche Médicale
  • Vaccine Research Institute

Zitieren

APA

Wiedemann, A., Surénaud, M., Hubert, M., Lopez Zaragoza, J. L., Ribeiro, A., Rodrigues, C., Foucat, E., Diombera, H., Krief, C., Schwartz, O., Lelièvre, J. D., & Lévy, Y. (2025). Characterization and comparison of immunity against MPXV for individuals infected with MPXV or vaccinated with modified vaccinia Ankara vaccines. The Journal of Immunology. https://doi.org/10.1093/jimmun/vkae031

Vancouver

Wiedemann A, Surénaud M, Hubert M, Lopez Zaragoza JL, Ribeiro A, Rodrigues C, et al. Characterization and comparison of immunity against MPXV for individuals infected with MPXV or vaccinated with modified vaccinia Ankara vaccines. The Journal of Immunology. 2025. doi:10.1093/jimmun/vkae031

BibTeX
@article{Wiedemann2025,
  author = {Wiedemann, Aurélie and Surénaud, Mathieu and Hubert, Mathieu and Lopez Zaragoza, José-Luis and Ribeiro, Alexandre and Rodrigues, Cécile and Foucat, Emile and Diombera, Harouna and Krief, Corinne and Schwartz, Olivier and Lelièvre, Jean-Daniel and Lévy, Yves},
  title = {Characterization and comparison of immunity against MPXV for individuals infected with MPXV or vaccinated with modified vaccinia Ankara vaccines},
  journal = {The Journal of Immunology},
  year = {2025},
  doi = {10.1093/jimmun/vkae031}
}
Kostenlos starten →